Pharmaceutical

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid TumorsFLORHAM PARK, N.J. and GARCHING, Germany and…

3 months ago

Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units

CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global…

3 months ago

Biodesix Announces One-for-Twenty Reverse Stock Split

LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized…

3 months ago

Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution

Expands Amneal’s Affordable Medicines portfolio and broadens patient accessBRIDGEWATER, N.J, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal”…

3 months ago

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

 Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain and function in Phase IIa trial in primary osteoarthritis patients   Six-month…

3 months ago

FOXO TECHNOLOGIES INC. ANNOUNCES ACQUISITION AGREEMENT TO ACQUIRE VECTOR BIOSOURCE INC.

WEST PALM BEACH, FL, Sept. 11, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (the “Company”), announces that it has signed a…

3 months ago

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing…

3 months ago

Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation…

3 months ago

A Landmark Pivotal Study Applying Precision Medicine to Psychiatry with Denovo’s DB104 (liafensine) for Treatment-Resistant Depression Published in JAMA Psychiatry

The study represents the first successful prospective genetic biomarker-guided drug trial in psychiatrySAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) --…

3 months ago